613 related articles for article (PubMed ID: 19852963)
41. Diagnostic Value of Serum Biomarkers for Patients Undergoing Curative Resection with Non-B, Non-C Hepatocellular Carcinoma.
Li Y; Chen Y; Chen J
J Coll Physicians Surg Pak; 2020 Feb; 30(2):134-138. PubMed ID: 32036818
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic utility of alpha-fetoprotein and des-gamma-carboxyprothrombin in nigerians with hepatocellular carcinoma.
Ette AI; Ndububa DA; Adekanle O; Ekrikpo U
Niger J Clin Pract; 2017 Oct; 20(10):1267-1272. PubMed ID: 29192630
[TBL] [Abstract][Full Text] [Related]
43. The diagnostic value of the assay of des-gamma-carboxy prothrombin in the detection of small hepatocellular carcinoma.
Chan CY; Lee SD; Wu JC; Lin HC; Huang YS; Lo GH; Lee FY; Tsai YT; Lo KJ
J Hepatol; 1991 Jul; 13(1):21-4. PubMed ID: 1717542
[TBL] [Abstract][Full Text] [Related]
44. Associated measurement of fucosylated levels of AFP, DCP, and GPC3 for early diagnosis in hepatocellular carcinoma.
Wu M; Liu Z; Zhang A; Li N
Int J Biol Markers; 2019 Mar; 34(1):20-26. PubMed ID: 30854929
[TBL] [Abstract][Full Text] [Related]
45. Determination of optimum cutoff levels of plasma des-gamma-carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves.
Fujiyama S; Izuno K; Yamasaki K; Sato T; Taketa K
Tumour Biol; 1992; 13(5-6):316-23. PubMed ID: 1283927
[TBL] [Abstract][Full Text] [Related]
46. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2001 Nov; 16(11):1290-6. PubMed ID: 11903749
[TBL] [Abstract][Full Text] [Related]
47. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Yamaguchi A; Isogai M; Kaneoka Y; Washizu J
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):111-7. PubMed ID: 16431313
[TBL] [Abstract][Full Text] [Related]
48. Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case-control study.
Ette AI; Ndububa DA; Adekanle O; Ekrikpo U
BMC Gastroenterol; 2015 Sep; 15():113. PubMed ID: 26341083
[TBL] [Abstract][Full Text] [Related]
49. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.
Volk ML; Hernandez JC; Su GL; Lok AS; Marrero JA
Cancer Biomark; 2007; 3(2):79-87. PubMed ID: 17522429
[TBL] [Abstract][Full Text] [Related]
50. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
51. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
[TBL] [Abstract][Full Text] [Related]
52. Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma.
Fujiyama S; Izuno K; Gohshi K; Shibata J; Sato T
Dig Dis Sci; 1991 Dec; 36(12):1787-92. PubMed ID: 1721019
[TBL] [Abstract][Full Text] [Related]
53. Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma.
Kim SU; Park JH; Kim HS; Lee JM; Lee HG; Kim H; Choi SH; Baek S; Kim BK; Park JY; Kim DY; Ahn SH; Lee JD; Han KH
Yonsei Med J; 2015 Sep; 56(5):1296-306. PubMed ID: 26256972
[TBL] [Abstract][Full Text] [Related]
54. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
[TBL] [Abstract][Full Text] [Related]
55. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
Dohmen K; Shigematsu H; Irie K; Ishibashi H
Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol.
Huang TS; Shyu YC; Turner R; Chen HY; Chen PJ
Syst Rev; 2013 Jun; 2():37. PubMed ID: 23738605
[TBL] [Abstract][Full Text] [Related]
57. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
[TBL] [Abstract][Full Text] [Related]
58. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
[TBL] [Abstract][Full Text] [Related]
59. The Predictive Power of Serum α-Fetoprotein and Des-γ-Carboxy Prothrombin for Survival Varies by Tumor Size in Hepatocellular Carcinoma.
Tsugawa D; Fukumoto T; Kido M; Takebe A; Tanaka M; Kuramitsu K; Matsumoto I; Ajiki T; Koyama T; Ku Y
Kobe J Med Sci; 2015 Mar; 61(5):E124-31. PubMed ID: 27363395
[TBL] [Abstract][Full Text] [Related]
60. Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.
Arai T; Kobayashi A; Ohya A; Takahashi M; Yokoyama T; Shimizu A; Motoyama H; Furusawa N; Notake T; Kitagawa N; Sakai H; Imamura H; Kadoya M; Miyagawa S
Int J Clin Oncol; 2014 Oct; 19(5):871-9. PubMed ID: 24218280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
